Boris Shore
President chez NORTHERN POTASH CO.
Postes actifs de Boris Shore
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NORTHERN POTASH CO. | President | - | - |
| Directeur Général | - | - |
Historique de carrière de Boris Shore
Anciens postes connus de Boris Shore
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Boris Shore
| Moscow University | Undergraduate Degree |
Statistiques
Internationale
| Russie | 3 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Executive Officer | 1 |
| President | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Process Industries | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NORTHERN POTASH CO. | Process Industries |
| Entreprise privées | 1 |
|---|---|
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Bourse
- Insiders
- Boris Shore
- Expérience
